Marcus Bosenberg

Professor

Yale University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.

Year:

2025

Despite promise in preclinical models, most immuno-oncology drug candidates fail in clinical trials. These failures reflect limitations in our ability to directly model the response of human tumor and immune cells to immunotherapies. To address this gap and test the effect of innate immune agonists, we developed PERCEPT, an approach that uses ex vivo perturbational single-cell RNA sequencing to compare the response of immunomodulatory treatments with unstimulated controls directly in patient samples. Using PERCEPT, we tested cytokines and innate immune agonists in melanoma and Merkel cell carcinoma (MCC) and identified the dsRNA mimetic, RIG-I agonist, Stem Loop RNA (SLR) 14 as a powerful inducer of anti-viral states and enhancer of T cell activation. We compared transcriptional ‘responder’ and ‘non-responder’ patient samples and identified midkine (MDK), a multifunctional cytokine, as a potent repressor of IFN signaling in both tumor and immune cells. MDK expression dampened MHC-I presentation in human tumor cells and reduced activation of antigen-presenting cells, disrupting tumor immunity at multiple levels. In contrast to prior studies, we identified MDK as specifically enriched in neuroendocrine cancers such as MCC and small cell lung cancer compared with melanoma, suggesting the importance of lineage- and context-specific targeting. Our results demonstrate the utility of high-dimensional controlled perturbation of patient samples to identify mechanisms of innate immune response and resistance and demonstrate an actionable path towards clinical development of MDK-inhibiting therapies including FDA-approved ALK inhibitors in neuroendocrine cancers.

Year:

2025

Identifying factors that mediate successful anticancer immune responses is necessary to improve outcomes for patients with advanced cancers. In this study, we performed single-cell RNA sequencing on mouse melanomas experiencing successful and unsuccessful immune responses and discovered a prominent ferroptosis signature in tumors undergoing immune-mediated regression. Pairing ferroptosis inducers and inhibitors with immunotherapies ex vivo and in vivo highlighted a central role for ferroptosis in stimulating the antimelanoma immune response. In coculture models, CD8 + T cells drove melanoma cell ferroptosis by altering the expression of glutathione peroxidase 4 (GPX4), a crucial antioxidant enzyme known for its role in preventing lipid peroxidation. Direct contact between tumor cells and CD8 + T cells was needed to sustain GPX4 downregulation over time, resulting in ferroptotic cell death. Finally, single-cell RNA sequencing data from human melanoma tumors responding to immunotherapy revealed a ferroptosis signature that mirrors the mouse model. Together, these results offer crucial insights into the role of ferroptosis in antitumor immunity and highlight the potential of modulating ferroptosis to enhance immunotherapy responses. Significance: CD8 + T cells directly interact with melanoma cells to downregulate the essential antioxidant enzyme GPX4 and stimulate ferroptosis, which is a crucial driver of immune cell-mediated melanoma clearance.

Year:

2025

BRAF V600E mutations occur in 46% of melanomas and drive high levels of ERK activity and ERK-dependent proliferation. However, BRAF V600E is insufficient to drive melanoma in genetically engineered mouse models, and 82% of human benign nevi harbor BRAF V600E mutations. We found that BRAF V600E inhibited mesenchymal migration by causing feedback inhibition of RAC1 activity. ERK pathway inhibition induced RAC1 activation and restored migration and invasion. In cells with BRAF V600E , mutant RAC1 or PTEN inactivation restored RAC1 activity and cell motility. Together, these lesions occurred in 26% of melanomas with BRAF V600E mutations. Thus, although BRAF V600E activation of ERK deregulates cell proliferation, it prevents full malignant transformation by causing feedback inhibition of RAC1. Secondary mutations are, therefore, required for tumorigenesis. One mechanism underlying tumor evolution may be the selection of lesions that rescue the deleterious effects of oncogenic drivers. Significance: Secondary genetic lesions that rescue BRAF V600E /ERK-induced feedback inhibition on cell migration are required for tumorigenesis, indicating that oncogenic feedback may shape the genetic landscape and select for mutations that are therapeutic targets.

Year:

2025

BRAF V600E mutations occur in 46% of melanomas and drive high levels of ERK activity and ERK-dependent proliferation. However, BRAFV600E is insufficient to drive melanoma in genetically engineered mouse models, and 82% of human benign nevi harbor BRAFV600E mutations. We found that BRAFV600E inhibited mesenchymal migration by causing feedback inhibition of RAC1 activity. ERK pathway inhibition induced RAC1 activation and restored migration and invasion. In cells with BRAFV600E, mutant RAC1 or PTEN inactivation restored RAC1 activity and cell motility. Together, these lesions occurred in 26% of melanomas with BRAFV600E mutations. Thus, although BRAFV600E activation of ERK deregulates cell proliferation, it prevents full malignant transformation by causing feedback inhibition of RAC1. Secondary mutations are, therefore, required for tumorigenesis. One mechanism underlying tumor evolution may be the selection of lesions that rescue the deleterious effects of oncogenic drivers. Significance: Secondary genetic lesions that rescue BRAFV600E/ERK-induced feedback inhibition on cell migration are required for tumorigenesis, indicating that oncogenic feedback may shape the genetic landscape and select for mutations that are therapeutic targets.

Year:

2025

Tumor-associated macrophages (TAM) are a heterogeneous population of myeloid cells that dictate the inflammatory tone of the tumor microenvironment. In this study, we unveiled a mechanism by which scavenger receptor cluster of differentiation 36 (CD36) suppresses TAM inflammatory states. CD36 was upregulated in TAMs and associated with immunosuppressive features, and myeloid-specific deletion of CD36 significantly reduced tumor growth. Moreover, CD36-deficient TAMs acquired inflammatory signatures including elevated type-I IFN (IFNI) production, mirroring the inverse correlation between CD36 and IFNI response observed in patients with cancer. IFNI, especially IFNβ, produced by CD36-deficient TAMs directly induced tumor cell quiescence and delayed tumor growth. Mechanistically, CD36 acted as a natural suppressor of IFNI signaling in macrophages through p38 activation downstream of oxidized lipid signaling. These findings establish CD36 as a critical regulator of TAM function and the tumor inflammatory microenvironment, providing additional rationale for pharmacologic inhibition of CD36 to rejuvenate antitumor immunity. Significance: CD36 in tumor-associated macrophages mediates immunosuppression and can be targeted as a therapeutic avenue for stimulating interferon production and increasing the efficacy of immunotherapy.

Year:

2025

Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components of the human silencing hub complex. We found that loss of Setdb1 leads to increased immunogenicity and complete tumor clearance in a CD8 + T cell–dependent manner. Mechanistically, loss of Setdb1 causes de-repression of endogenous retroviruses (ERV) in melanoma cells and triggers tumor cell–intrinsic type I IFN signaling, upregulation of MHC-I expression, and increased CD8 + T-cell infiltration. Importantly, spontaneous immune clearance observed in Setdb1 −/− tumors results in subsequent protection from other ERV-expressing tumor lines, supporting the functional antitumor role of ERV-specific CD8 + T cells found in the Setdb1 −/− microenvironment. Blocking the type I IFN receptor in mice grafted with Setdb1 −/− tumors decreases immunogenicity by decreasing MHC-I expression, leading to decreased T-cell infiltration and increased melanoma growth, comparable with Setdb1 wt tumors. Together, these results provide key in vivo evidence of a critical role for Setdb1 and type I IFNs in generating an inflamed tumor microenvironment and potentiating tumor cell–intrinsic immunogenicity in melanoma. This study further emphasizes regulators of ERV expression and type I IFN expression as potential therapeutic targets for augmenting anticancer immune responses.

Year:

2025

Checkpoint inhibitors have revolutionized cancer treatment, but resistance remains a significant clinical challenge. Myeloid cells within the tumor microenvironment can modulate checkpoint resistance by either supporting or suppressing adaptive immune responses. Using an anti–PD-1–resistant mouse melanoma model, we show that targeting the myeloid compartment via CD40 activation and CSF1R blockade in combination with anti–PD-1 results in complete tumor regression in a majority of mice. This triple therapy combination was primarily CD40 agonist-driven in the first 24 hours after therapy and showed a similar systemic cytokine profile in human patients as was seen in mice. Functional single-cell cytokine secretion profiling of dendritic cells (DC) using a novel microwell assay identified a CCL22 + CCL5 + IL12-secreting DC subset as important early-stage effectors of triple therapy. CD4 + and CD8 + T cells are both critical effectors of treatment, and systems analysis of single-cell RNA sequencing data supported a role for DC-secreted IL12 in priming T-cell activation and recruitment. Finally, we showed that treatment with a novel IL12 mRNA therapeutic alone was sufficient to overcome PD-1 resistance and cause tumor regression. Overall, we conclude that combining myeloid-based innate immune activation and enhancement of adaptive immunity is a viable strategy to overcome anti–PD-1 resistance.

Year:

2025

Effective cancer immunotherapies restore anti-tumor immunity by rewiring cell-cell communication. Treatment-induced changes in communication can be inferred from single-cell RNA-sequencing (scRNA-seq) data, but current methods do not effectively manage heterogeneity within cell types. Here we developed a computational approach to efficiently analyze scRNA-seq-derived, single-cell-resolved cell-cell interactomes, which we applied to determine how agonistic CD40 (CD40ag) alters immune cell crosstalk alone, across tumor models, and in combination with immune checkpoint blockade (ICB). Our analyses suggested that CD40ag improves responses to ICB by targeting both immuno-stimulatory and immunosuppressive macrophage subsets communicating with T cells, and we experimentally validated a spatial basis for these subsets with immunofluorescence and spatial transcriptomics. Moreover, treatment with CD40ag and ICB established coordinated myeloid-T cell interaction hubs that are critical for reestablishing antitumor immunity. Our work advances the biological significance of hypotheses generated from scRNA-seq-derived cell-cell interactomes and supports the clinical translation of myeloid-targeted therapies for ICB-resistant tumors.

Year:

2024

Checkpoint inhibitors have revolutionized cancer treatment, but resistance remains a significant clinical challenge. Myeloid cells within the tumor microenvironment can modulate checkpoint resistance by either supporting or suppressing adaptive immune responses. Using an anti-PD-1-resistant mouse melanoma model, we show that targeting the myeloid compartment via CD40 activation and CSF1R blockade in combination with anti-PD-1 results in complete tumor regression in a majority of mice. This triple therapy combination was primarily CD40 agonist-driven in the first 24 hours post-therapy and showed a similar systemic cytokine profile in human patients as was seen in mice. Functional single-cell cytokine secretion profiling of dendritic cells (DCs) using a novel microwell assay identified a CCL22+CCL5+ IL12-secreting DC subset as important early-stage effectors of triple therapy. CD4+ and CD8+ T cells are both critical effectors of treatment, and systems analysis of single-cell RNA-sequencing data supported a role for DC-secreted IL12 in priming T-cell activation and recruitment. Finally, we showed that treatment with a novel IL12 mRNA therapeutic alone was sufficient to overcome PD-1 resistance and cause tumor regression. Overall, we conclude that combining myeloid-based innate immune activation and enhancement of adaptive immunity is a viable strategy to overcome anti-PD-1 resistance.

Year:

2024

Collaborators (39)

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES
View details

Qin Yan

Anthony N. Brady Professor of Pathology

Yale University

UNITED STATES
View details

Benjamin E. Turk

Yale University School of Medicine

UNITED STATES
View details

Yuting Lu

New York University

UNITED STATES
View details

Graham Mann

Professor

University of Sydney

AUSTRALIA
View details

Adam Reynolds

Research Assistant Professor

University of New Mexico

UNITED STATES
View details

Shaofeng Yan

-

UNITED STATES
View details

Goran Micevic

Yale University

UNITED STATES
View details

Yongzhao Shao

New York University Grossman School of Medicine

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Cheryl Thompson

Professor and Associate Director for Population Sciences, Penn State Cancer Institute

Pennsylvania State University

UNITED STATES
View details

Susan Kaech

Director & Professor

Salk Institute for Biological Studies

UNITED STATES
View details

Kathryn Miller-Jensen

Associate Professor

Yale University

UNITED STATES
View details

Christopher I. Amos

Associate Director for Population and Data Science

Baylor College of Medicine

UNITED STATES
View details

David Calderwood

Yale University School of Medicine

UNITED STATES
View details

Philippos Apolinario Costa

Assistant Professor

Yale New Haven Hospital

UNITED STATES
View details

Pauline Funchain

Stanford University

UNITED STATES
View details

Harriet Kluger

Yale University School of Medicine

UNITED STATES
View details

Marianne Berwick

Professor

University of New Mexico

UNITED STATES
View details

Akiko Iwasaki

Professor

Yale University School of Medicine

UNITED STATES
View details

David Ollila

Professor of Surgery

University of North Carolina at Chapel Hill

UNITED STATES
View details

Marc Ernstoff

Chief

National Institutes of Health

UNITED STATES
View details

William Damsky

Associate Professor of Dermatology

Yale University

UNITED STATES
View details

Anne E Cust

Deputy Director, The Daffodil Centre

University of Sydney

AUSTRALIA
View details

David Polsky

Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)

NYU School of Medicine

UNITED STATES
View details

Tim Lee

The University of British Columbia

UNITED STATES
View details

Pei-Fen Kuan

Professor

Stony Brook University

UNITED STATES
View details

Rong Fan

Harold Hodgkinson Professor of Biomedical Engineering

Yale University

UNITED STATES
View details

Paul Googe

Professor and Laboratory Director

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dan Chen

Salk Institute for Biological Studies

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Iman Osman

NYU Langone Health

UNITED STATES
View details

Eva Hernando

Professor

NYU Langone Medical Center

UNITED STATES
View details

Sheri L. Holmen

Professor

University of Utah Health Sciences Center

UNITED STATES
View details

Simon F Roy

Assistant Professor

McGill University

CANADA
View details

Amin Nassar

Yale University

UNITED STATES
View details

David van Dijk

Assistant Professor

Yale University

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

E. Nagore

Profesor Asociado

Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología

SPAIN
View details